FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Natasha Leighl

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Canada

Co-author Network

Publications

TOP 3
D Marshall; K Pykerman; M Trudeau; Y Bombard; Natasha B Leighl; K Deal
Patient preferences: understanding risk-benefit trade-offs of genomic testing in chemotherapy decisions for breast cancer patients.
S Djalalov; Jeffrey S Hoch; M Krahn; J Beca; J C Cutz; M S Tsao; Natasha B Leighl
Cost-effectiveness of eml4-alk fusion testing in combination with crizotinib treatment for patients with advanced non-small cell lung cancer living in ontario.
Petra Martin; Natasha B Leighl; Ming-Sound Tsao; Frances A Shepherd
KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Natasha Leighl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: D Marshall; K Pykerman; M Trudeau; Y Bombard; Natasha B Leighl; K Deal
Patient preferences: understanding risk-benefit trade-offs of genomic testing in chemotherapy decisions for breast cancer patients.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2013;16(3):A147-8.
2013: S Djalalov; Jeffrey S Hoch; M Krahn; J Beca; J C Cutz; M S Tsao; Natasha B Leighl
Cost-effectiveness of eml4-alk fusion testing in combination with crizotinib treatment for patients with advanced non-small cell lung cancer living in ontario.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2013;16(3):A142.
2013: Petra Martin; Natasha B Leighl; Ming-Sound Tsao; Frances A Shepherd
KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(5):530-42.
2013: Adrian G Sacher; Lisa W Le; Natasha B Leighl; Linda E Coate
Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(3):366-8.
2013: Ilia L Ferrusi; Jeffrey S Hoch; Hoa Khong; Natasha B Leighl; Eleanor Pullenayegum; Maureen Trudeau; Craig C Earle; Deborah A Marshall
Closing the personalized medicine information gap: HER2 test documentation practice.
The American journal of managed care 2013;19(1):838-44.
2013: Peter M Ellis; Holger Fritsch; Birgit Gaschler-Markefski; Steve Gyorffy; Scott A Laurie; Natasha B Leighl; Quincy S Chu; Gerd Munzert
A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Clinical lung cancer 2013;14(1):19-27.
2012: Massimo Di Maio; Morena Fasano; Adolfo Favaretto; Ronald Feld; Raffaella Felletti; Vittorio Fregoni; Ciro Gallo; Vittorio Gebbia; Giovenzio Genestreti; Cesare Gridelli; Natasha B Leighl; Paolo Maione; Gianfranco Mancuso; Alessandro Morabito; Floriana Morgillo; Francesco Perrone; Alberto Ravaioli; Ferdinando Riccardi; Antonio Rossi; Salvatore Siena; Simona Signoriello; Mario Spatafora; Ming Sound Tsao; Rafal Wierzbicki; Yasmin Alam; Roberto Bianco; Charles Butts; Fortunato Ciardiello; Saverio Cinieri
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(12):1830-44.
2012: Natasha B Leighl
Positron emission tomography use and stage migration in lung cancer: a false sense of accomplishment?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(22):2710-1.
2012: Anne M Horgan; Jennifer J Knox; Natasha B Leighl; Geoffrey Liu; Prakruthi Palepu; Nicole Perera; Linda Coate; Marjan Emami; Shabbir M H Alibhai
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study.
American journal of clinical oncology 2012;35(4):322-8.
2012: Sri Navaratnam; Janet Nowatzki; Gefei Qing; Frances A Shepherd; GEORGIOS SKLIRIS; Dongsheng Tu; Ketan Badiani; Shantanu Banerji; Penelope A Bradbury; Alain Demers; Natasha B Leighl; Leigh Murphy
Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.
Hormones & cancer 2012;3(3):93-100.
2012: Nicole Mittmann; Stuart Peacock; Angela Rocchi; Suzanne C Malfair Taylor; Heather-Jane Au; Doug Coyle; William K Evans; Don Husereau; Pierre K Isogai; Philip Jacobs; Murray D Krahn; Natasha B Leighl; Christopher J Longo; Deborah Marshall; Paul I Oh
Guidelines for health technologies: specific guidance for oncology products in Canada.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(3):580-5.
2012: Humberto Lara-Guerra; Natasha B Leighl; Melania Pintilie; Joerg Schwock; Catherine T Chung; David M Hwang; Thomas K Waddell; Ming Tsao
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2012;76(2):235-41.
2012: Meredith E Giuliani; Andrea Bezjak; Anthony Brade; John Cho; Lisa W Le; Natasha B Leighl; Patricia E Lindsay; Frances A Shepherd; Alexander Sun; Andrew J Hope
Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012;102(2):263-7.
2012: William Dubinski; Natasha B Leighl; Ming-Sound Tsao; David M Hwang
Ancillary testing in lung cancer diagnosis.
Pulmonary medicine 2012;2012():249082.
2011: Sinead Cuffe; Natasha B Leighl
Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(11 Suppl 4):S1805-7.
2011: Meredith E Giuliani; Soha Atallah; Andrea Bezjak; Anthony Brade; John Cho; Lisa W Le; Natasha B Leighl; Frances A Shepherd; Alexander Sun; Andrew J Hope
Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.
Clinical lung cancer 2011;12(6):375-9.
2011: Peter M Ellis; Diana N Ionescu; Meenakshi Kashyap; Geoff Liu; Barb Melosky; Tony Reiman; Phillippe Romeo; Frances A Shepherd; Dennis Soulieres; Ming-Sound Tsao; Normand Blais; Natasha B Leighl
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(8):1379-91.
2011: A M Horgan; E S Kim; E Amir; P A Bradbury; J Y Douillard; R Ng; Frances A Shepherd; Natasha B Leighl
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(8):1805-11.
2011: Natasha B Leighl; Heather L Shepherd; Phyllis N Butow; Stephen J Clarke; Margaret McJannett; Philip J Beale; Nicholas R C Wilcken; Malcolm J Moore; Eric X Chen; David Goldstein; Lisa Horvath; Jennifer J Knox; Monika K Krzyzanowska; Amit Oza; Ronald Feld; David Hedley; Wei Xu; Martin H N Tattersall
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2077-84.
2011: Ilia L Ferrusi; Nathalie A Kulin; Natasha B Leighl; Deborah A Marshall
Do economic evaluations of targeted therapy provide support for decision makers?
Journal of oncology practice / American Society of Clinical Oncology 2011;7(3 Suppl):36s-45s.
2011: Ilia L Ferrusi; Nathalie A Kulin; Natasha B Leighl; Deborah A Marshall
Do economic evaluations of targeted therapy provide support for decision makers?
The American journal of managed care 2011;17 Suppl 5 Developing():SP61-70.
2011: Linda E Coate; Natasha B Leighl
How affordable are targeted therapies in non-small cell lung cancer?
Current treatment options in oncology 2011;12(1):1-11.
2011: Natasha B Leighl; J Bennouna; J Yi; N Moore; J Hambleton; H Hurwitz
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.
British journal of cancer 2011;104(3):413-8.
2011: Primo Lara; Jeff Longmate; Karen Reckamp; Barbara Gitlitz; Athanassios Argiris; Suresh Ramalingam; Chandra P Belani; Philip C Mack; Derick H Lau; Mariana Koczywas; John J Wright; Frances A Shepherd; Natasha B Leighl; David R Gandara
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Clinical lung cancer 2011;12(1):33-7.
2011: Arman Hasani; Natasha B Leighl
Classification and toxicities of vascular disrupting agents.
Clinical lung cancer 2011;12(1):18-25.
2010: Meredith Giuliani; Alexander Sun; Andrea Bezjak; Clement Ma; Lisa W Le; Anthony Brade; John Cho; Natasha B Leighl; Frances A Shepherd; Andrew J Hope
Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma.
Cancer 2010;116(24):5694-9.
2010: Raymond W Jang; Pierre K Isogai; Nicole Mittmann; Penelope A Bradbury; Frances A Shepherd; Ronald Feld; Natasha B Leighl
Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):1953-7.
2010: Arman Hasani; Natasha B Leighl
Targeting vascular endothelial growth factor in lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12 Suppl 6):S484-6.
2010: Natasha B Leighl; Petr Zatloukal; Jörg Mezger; Rodryg Ramlau; Nicola Moore; Martin Reck; Christian Manegold
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):1970-6.
2010: Paul Wheatley-Price; Boming Yang; Demetris Patsios; Devalben Patel; Clement Ma; Wei Xu; Natasha B Leighl; Ronald Feld; B C John Cho; Brenda O'Sullivan; Heidi Roberts; Ming Tsao; Martin Tammemagi; Masaki Anraku; Zhuo Chen; Marc De Perrot; Geoffrey Liu
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(20):3316-22.
2010: Natasha B Leighl; Luis E Raez; Benjamin Besse; Peter J Rosen; Fabrice Barlesi; E Massarelli; Nashat Gabrail; Lowell L Hart; Kathy S Albain; Lloyd Berkowitz; Ostap Melnyk; Frances A Shepherd; Lars Sternas; Judie Ackerman; Zhenming Shun; Vincent A Miller; Roy S Herbst
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):1054-9.
2010: Penelope A Bradbury; Dongsheng Tu; Lesley Seymour; Pierre K Isogai; Liting Zhu; Raymond Ng; Nicole Mittmann; Ming-Sound Tsao; William K Evans; Frances A Shepherd; Natasha B Leighl
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Journal of the National Cancer Institute 2010;102(5):298-306.
2010: Sara K Taylor; Stephen Chia; Susan Dent; Mark Clemons; Mark Agulnik; Pamela Grenci; Lisa Wang; Amit M Oza; Percy Ivy; Kathleen I Pritchard; Natasha B Leighl
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
The oncologist 2010;15(8):810-8.
2010: Glenwood D Goss; Andrew Arnold; Frances A Shepherd; Mircea Dediu; Tudor-Eliade Ciuleanu; David Fenton; Mauro Zukin; David Walde; Francis Laberge; mark vincent; Peter M Ellis; Scott A Laurie; Keyue Ding; Eliot Frymire; Isabelle Gauthier; Natasha B Leighl; Cheryl Ho; Jonathan Noble; Christopher W Lee; Lesley Seymour
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):49-55.
2009: Humberto Lara-Guerra; Thomas K Waddell; Maria A Salvarrey; Anthony M Joshua; Catherine T Chung; Narinder Paul; Scott Boerner; Akira Sakurada; Olga Ludkovski; Clement Ma; Jeremy Squire; Geoffrey Liu; Frances A Shepherd; Ming Tsao; Natasha B Leighl
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6229-36.
2009: Lisa K Hicks; Matthew C Cheung; Keyue Ding; Baktiar Hasan; Lesley Seymour; Aurélie Le Maître; Natasha B Leighl; Frances A Shepherd
Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
Cancer 2009;115(23):5516-25.
2009: Raymond W Jang; Aurélie Le Maître; Keyue Ding; Timothy Winton; Andrea Bezjak; Lesley Seymour; Frances A Shepherd; Natasha B Leighl
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4268-73.
2009: Natasha B Leighl; Scott A Laurie; Xueyu E Chen; Peter Ellis; Frances A Shepherd; Jennifer J Knox; Glenwood Goss; Ronald L Burkes; Gregory R Pond; Christopher Dick; Yun Yen; James A Zwiebel; Malcolm J Moore
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(9):1163-9.
2009: Winson Y Cheung; David M Hwang; Tae Bong Chung; Michael R Johnston; Natasha B Leighl
Initial treatment strategies and outcomes for multifocal bronchioloalveolar carcinoma.
Clinical lung cancer 2009;10(3):187-92.
2009: Masaki Anraku; Thomas K Waddell; Marc De Perrot; Stephen J Lewis; Andrew F Pierre; Gail Darling; Michael R Johnston; Rebecca E Zener; Y Raja Rampersaud; Frances A Shepherd; Natasha B Leighl; Andrea Bezjak; Alexander Y Sun; David M Hwang; Ming Tsao; Shaf Keshavjee
Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine.
The Journal of thoracic and cardiovascular surgery 2009;137(2):441-447.e1.
2009: Simon J Crabb; Demetris Patsios; Eric Sauerbrei; Peter M Ellis; Andrew Arnold; Glenwood Goss; Natasha B Leighl; Frances A Shepherd; Jean Powers; Lesley Seymour; Scott A Laurie
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(3):404-10.
2008: Raymond Ng; Michael Loreto; Roy Lee; Natasha B Leighl
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2008;61(2):262-5.
2008: Natasha B Leighl; Frances A Shepherd; D Zawisza; R L Burkes; Ronald Feld; J Waldron; A Sun; D Payne; A Bezjak; Martin H N Tattersall
Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer.
British journal of cancer 2008;98(11):1769-73.
2008: Anne Horgan; Ronald Feld; Natasha B Leighl
Gefitinib: a consideration of cost.
Expert review of pharmacoeconomics & outcomes research 2008;8(3):223-32.
2008: Kimberly S Chiew; Heather Shepherd; Janette Vardy; Martin H N Tattersall; Phyllis N Butow; Natasha B Leighl
Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer.
Health expectations : an international journal of public participation in health care and health policy 2008;11(1):35-45.
2008: Natasha B Leighl; Susan Dent; Mark Clemons; Theodore A Vandenberg; Richard Tozer; David Warr; R Michael Crump; David Hedley; Gregory R Pond; Janet E Dancey; Malcolm J Moore
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Breast cancer research and treatment 2008;108(1):87-92.
2008: Kathryn L Howe; Natasha B Leighl
Factors contributing to adjuvant therapy decisions.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):195-6.
2008: Timothy R Asmis; Keyue Ding; Lesley Seymour; Frances A Shepherd; Natasha B Leighl; Timothy Winton; Marlo Whitehead; Johanna N Spaans; Barbara C Graham; Glenwood D Goss
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):54-9.
2007: Raymond Ng; Baktiar Hasan; Nicole Mittmann; Marie Florescu; Frances A Shepherd; Keyue Ding; Charles Butts; Yvon Cormier; Gail Darling; Glenwood Goss; Richard Inculet; Lesley Seymour; Timothy Winton; William K Evans; Natasha B Leighl
Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2256-61.
2007: Rachel Benamore; Frances A Shepherd; Natasha B Leighl; Melania Pintilie; Milan Patel; Ronald Feld; Stephen Herman
Does intensive follow-up alter outcome in patients with advanced lung cancer?
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(4):273-81.
2007: Leora Horn; Antonio Visbal; Natasha B Leighl
Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics.
Drugs & aging 2007;24(5):411-28.
2007: Farrah Kassam; Frances A Shepherd; Michael Johnston; Antonio Visbal; Ronald Feld; Gail Darling; Shaf Keshavjee; Andrew F Pierre; Thomas K Waddell; Natasha B Leighl
Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(1):39-43.
2006: Natasha B Leighl; Glenwood Goss; P G Lopez; Ronald L Burkes; Janet E Dancey; Y H Rahim; L C Rudinskas; J F Pouliot; A Rodgers; Gregory R Pond; Frances A Shepherd
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2006;52(3):327-32.
2006: Natasha B Leighl; W Stephen Tsao; Dianne L Zawisza; Mahsan Nematollahi; Frances A Shepherd
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2006;51(1):115-21.
2005: Wenjiang Zhang; Natasha B Leighl; Diane Zawisza; Malcolm J Moore; Eric X Chen
Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;829(1-2):45-9.
2005: Antonio Visbal; Natasha B Leighl; Ronald Feld; Frances A Shepherd
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
Chest 2005;128(4):2933-43.
2005: Hannah Carolan; Alexander Y Sun; Andrea Bezjak; Qi-Long Yi; David Payne; Gabrielle Kane; John Waldron; Natasha B Leighl; Ronald Feld; Ronald L Burkes; Shaf Keshavjee; Frances A Shepherd
Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?
Lung cancer (Amsterdam, Netherlands) 2005;49(1):109-15.
2005: Giannicola D'Addario; Melania Pintilie; Natasha B Leighl; Ronald Feld; Thomas Cerny; Frances A Shepherd
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2926-36.
2005: Natasha B Leighl; Luis Paz-Ares; Jean-Yves Douillard; Christian Peschel; Andrew Arnold; Alain Depierre; Armando Santoro; Daniel C Betticher; Ulrich Gatzemeier; Jacek Jassem; Jeffrey Crawford; Dongsheng Tu; Andrea Bezjak; Jeff Humphrey; Maurizio Voi; Susan Galbraith; Katherine Hann; Lesley Seymour; Frances A Shepherd
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2831-9.
2005: Rebecca Hagerty; Phyllis N Butow; Peter M Ellis; Elizabeth A Lobb; Susan Pendlebury; Natasha B Leighl; Craig MacLeod; Craig Mac Leod; Martin H N Tattersall
Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1278-88.
2004: Natasha B Leighl; Phyllis N Butow; Martin H N Tattersall
Treatment decision aids in advanced cancer: when the goal is not cure and the answer is not clear.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1759-62.
2004: Rebecca Hagerty; Phyllis N Butow; Peter A Ellis; Elizabeth A Lobb; Susan Pendlebury; Natasha B Leighl; David Goldstein; Sing Kai Lo; Martin H N Tattersall
Cancer patient preferences for communication of prognosis in the metastatic setting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1721-30.
2003: Natasha B Leighl; Ronald L Burkes; Janet E Dancey; Pedro G Lopez; Brian P Higgins; P L David Walde; Leona C Rudinskas; Yasmin H Rahim; Angela Rodgers; Gregory R Pond; Frances A Shepherd
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
Clinical lung cancer 2003;5(2):107-12.
2003: Fiona H Blackhall; Melania Pintilie; Michael Michael; Natasha B Leighl; Ronald Feld; Ming Tsao; Frances A Shepherd
Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2241-7.
2002: Natasha B Leighl; Frances A Shepherd; Rita Kwong; Ronald L Burkes; Ronald Feld; Pamela J Goodwin
Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1344-52.
2001: Natasha B Leighl; M Gattellari; P Butow; R Brown; Martin H N Tattersall
Discussing adjuvant cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1768-78.